A paradigm of epigenetically driven resistance has recently been provided by Sharma et al. who reported the existence of a reversible drug-tolerant state in non-small cell lung cancer (NSCLC)-derived cell lines, and which can survive exposure to lethal concentrations of EGFR tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.